Cell therapy platform under Roche partnership with three early-stage bets riding on whether any one reaches proof-of-concept before Q3 2028 cash

Bull

Successful release testing confirms that the cGMP manufacturing run meets all quality specifications, enabling ReSonance to advance into in-vivo preclinical studies and subsequently toward IND-enabling work under the William Demant Invest collaboration framework. This outcome would validate the AlloSCOPE manufacturing platform in a second indication, de-risk the path to clinical proof-of-concept, and demonstrate that the $12 million collaboration funding is being deployed productively — materially improving the probability that ReSonance reaches a meaningful data readout before the cash constraint becomes binding.

Bear

Release testing failure — due to potency, sterility, identity, or yield shortfalls — would require additional engineering runs, consuming both time and the collaboration budget, and potentially compressing or eliminating the window available to generate clinical proof-of-concept before Q3 2028. The most likely failure modes are cell viability or functional potency assay failures given the complexity of auditory neuronal progenitor differentiation, or contamination events during the cGMP transition, either of which would force a manufacturing redesign that could push the program beyond the thesis-critical timeline.